Friday | August 12th 2022
CEO MESSAGE
International opportunities continue to abound for our talented sector, presenting excellent opportunities for growth and expansion. Recently, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of oncology medicines for cancer patients in China. Asahi Kasei Pharma, based in Tokyo, Japan, is putting out an open call for new proposals related to drug discovery research as part of its efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. Proposals will be officially accepted beginning early next year and interested applicants can learn more here.
 
Additionally, if you are an innovative digital health or medical technology company looking to scale up your operations and gain a foothold in Asia, the Canadian Trade Commissioner Service invites you to submit an application to the Healthcare Technology - Canadian Technology Accelerator. This unique development program will be hosted virtually, and will help organizations foster strategic partnerships, tap into the Taiwanese healthcare industry, validate your technology, and expand into Taiwan and Asia.
 
Industry Events

Industry events are an important contributor to our overall growth as a sector. They provide a platform for us to promote all the innovations that are on the horizon, while also facilitating important opportunities for networking and collaboration. Next Thursday, August 18th, SFU’s Chang Institute and Coast Capital Venture Connection in partnership with SFU VentureLabs and Genome BC are hosting a workshop entitled “Developing a Long-Term IP Strategy”, designed to teach science and technology entrepreneurs how to optimize their IP strategy. The 22nd Annual Healthcare Summit by Reboot Communications is also coming up on September 22nd and 23rd in Vancouver.
 
Kudos

It’s always exciting to see homegrown talent recognized internationally. Kudos to Tamer Mohamed, co-founder and CEO of Aspect Biosystems, for being included on Bloomberg New Economy’s 2022 class of Catalysts list, which includes a group of 28 remarkable individuals dedicated to creating a more equitable and sustainable future for all!
 
People on the Move
 
Congratulations to Michael Artley, who recently joined Acuitas Therapeutics as their new Senior Director of IT. Kudos to Nicole Lemerond for joining InMed Pharmaceuticals’ Board of Directors.
 
As a final note, this month also marks Genome BC's Pascal Spothelfer’s departure as President and CEO. As he prepares to make way for incoming President and CEO Suzanne Gill, we’re thrilled to highlight Mr. Spothelfer for his countless contributions to genomics and the life sciences sector as a whole, such as serving as one of LSBC’s Board of Directors for the past six years. We thank him for his continued involvement with our organization, and wish him well in this next chapter.
 
Until next week,
 
Wendy and the LSBC team
PLATINUM SPONSORS
First National Cannabis Trial for Cancer Symptoms Being Re-Opened
The first- national clinical trial of medical cannabis oil extracts for multiple cancer-related symptoms has re-opened and is recruiting patients and cancer survivors who continue to experience cancer-related symptoms. The study will evaluate three cannabis oils, using extracts already publicly available, on four cancer-related symptoms: nausea, pain, anxiety, and insomnia...READ MORE
Amgen Presents New Tarlatamab Clinical Data at WCLC 2022
Amgen announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3, in small cell lung cancer. Updated data from the ongoing Phase 1 study were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer in Vienna, Austria...READ MORE
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. and Global Blood Therapeutics (GBT), Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances Pfizer’s more than 30-year heritage in rare hematology and reinforces the company’s commitment to SCD by...READ MORE
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is more important than ever,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer...READ MORE
InMed Announces Changes to its Board of Directors
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets...READ MORE
INDUSTRY NEWS
Call for Applications: Canadian Technology Accelerator in Taiwan for Healthcare Technology
Are you looking to scale up your innovative digital health or medical technology company and gain a foothold in Asia? If so, the Canadian Trade Commissioner Service (TCS) invites you to apply for the Healthcare Technology – Canadian Technology Accelerator, a comprehensive virtual program designed to help your business foster strategic partnerships, tap into the Taiwanese healthcare industry, and expand to Taiwan and Asia at large...READ MORE
GOLD SPONSORS
Scientific Director, Research, Biologic Discovery – Experimental Immunology

If you feel like you’re part of something bigger, it’s because you are. At Amgen, our shared mission—to serve patients—drives all that we do. It is key to our becoming one of the world’s leading biotechnology companies. We are global collaborators who achieve together—researching, manufacturing, and delivering ever-better products that reach over 10 million patients worldwide. It’s time for a career you can be proud of. Join us.





Technician, Biochemistry


As a Technician at ABOzymes Biomedical you will be involved in a combination of protein biochemistry (protein purification and characterisation), enzymology (assay of enzymes, use of enzymes in synthesis of oligosaccharide substrates) and microbiology/molecular biology (gene cloning, mutagenesis, transformation etc.). The Technician must be able to take initiative in problem solving, prioritise assignments, work efficiently with short time constraints, and work with minimum supervision.

Tenure-Track Assistant Professor Position, Pharmacology

We now invite applications for a full-time tenure-track Assistant Professor position in Pharmacology. Applicants for this position must possess a PhD or equivalent doctoral qualification, with research expertise that broadens our current strengths in cancer pharmacology, cardiovascular pharmacology, diabetes, drug metabolism/pharmacokinetics, neuropharmacology, and pharmacogenomics or complements these strengths with a research focus in pharmacology.

SILVER SPONSORS
Discovery DNA reads 20,000 regions of DNA code or genes, that are linked to human growth, development and unfortunately, sometimes disease. All the steps in the Discovery DNA process are secure. Your DNA and data always stay in Canada and they will never sell your DNA sequence to anyone. The lab is now pending ISO 15189 certification, so you can be sure that your sample is handled according to industry standards.

YouCount is a health-tech company engineering next generation, at-home medical devices utilizing machine vision, analytics and sensors for bio-marker detection.

Their technology platform first screens and then tracks long-term bio-markers patterns, enabling users to make informed health-related decisions in real-time, thereby improving outcomes.


BRONZE SPONSORS
Post a Job on the LSBC Website!
LSBC Membership Discounts on Job Postings
 
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five posts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact talent@lifesciencesbc.ca